234 related articles for article (PubMed ID: 10998335)
1. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors.
Zhou H; Beaudet AL
Virology; 2000 Sep; 275(2):348-57. PubMed ID: 10998335
[TBL] [Abstract][Full Text] [Related]
2. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
4. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.
Hodges BL; Serra D; Hu H; Begy CA; Chamberlain JS; Amalfitano A
J Gene Med; 2000; 2(4):250-9. PubMed ID: 10953916
[TBL] [Abstract][Full Text] [Related]
5. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H; O'Neal W; Morral N; Beaudet AL
J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
[TBL] [Abstract][Full Text] [Related]
6. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
7. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.
Cheshenko N; Krougliak N; Eisensmith RC; Krougliak VA
Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932
[TBL] [Abstract][Full Text] [Related]
8. Generation of recombinant adenovirus vector with infectious adenoviral genome released from cosmid-based vector by simple procedure allowing complex manipulation.
Kojima H; Ohishi N; Yagi K
Biochem Biophys Res Commun; 1998 May; 246(3):868-72. PubMed ID: 9618304
[TBL] [Abstract][Full Text] [Related]
9. Degenerated pIX-IVa2 adenoviral vector sequences lowers reacquisition of the E1 genes during virus amplification in 293 cells.
Robert JJ; Gauffeny I; Maccario J; Jullien C; Benoit P; Vigne E; Crouzet J; Perricaudet M; Yeh P
Gene Ther; 2001 Nov; 8(22):1713-20. PubMed ID: 11892839
[TBL] [Abstract][Full Text] [Related]
10. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
11. A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.
Marzio G; Kerkvliet E; Bogaards JA; Koelewijn S; De Groot A; Gijsbers L; Weverling GJ; Vogels R; Havenga M; Custers J; Pau MG; Guichoux JY; Lewis J; Goudsmit J
Vaccine; 2007 Mar; 25(12):2228-37. PubMed ID: 17250936
[TBL] [Abstract][Full Text] [Related]
12. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
13. Human adenovirus type 35: nucleotide sequence and vector development.
Gao W; Robbins PD; Gambotto A
Gene Ther; 2003 Nov; 10(23):1941-9. PubMed ID: 14528318
[TBL] [Abstract][Full Text] [Related]
14. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations.
Alemany R; Dai Y; Lou YC; Sethi E; Prokopenko E; Josephs SF; Zhang WW
J Virol Methods; 1997 Nov; 68(2):147-59. PubMed ID: 9389404
[TBL] [Abstract][Full Text] [Related]
15. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
[TBL] [Abstract][Full Text] [Related]
16. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
17. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
18. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
19. Production of helper-dependent adenovirus vector relies on helper virus structure and complementing.
Zhou HS; Zhao T; Rao XM; Beaudet AL
J Gene Med; 2002; 4(5):498-509. PubMed ID: 12221643
[TBL] [Abstract][Full Text] [Related]
20. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production.
Schiedner G; Hertel S; Kochanek S
Hum Gene Ther; 2000 Oct; 11(15):2105-16. PubMed ID: 11044912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
